 | • レポートコード：QY7233NQ2009 • 出版社/出版日：QYResearch / 2026年10月 • レポート形態：英語、PDF、130ページ • 納品方法：Eメール（納期：2-3日） • 産業分類：医療 |
| Single User（1名様利用） | ￥452,400 (USD2,900) | ▷ お問い合わせ |
| Multi User（5名様利用） | ￥678,600 (USD4,350) | ▷ お問い合わせ |
| Corporate User（利用人数無制限） | ￥904,800 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 世界の体外受精（IVF）用マイクロマニピュレーションピペット市場は、2025年に3,872万米ドルと評価され、2026年から2032年にかけて年平均成長率（CAGR）5.4％で拡大し、2032年には5,596万米ドルに達すると予測されています。 体外受精（IVF）用マイクロマニピュレーションピペットは、生殖補助医療施設において細胞質内精子注入（ICSI）に使用される専用のマイクロマニピュレーションツールである。通常、先端が鋭利、面取り、またはスパイク状になった極細のガラスキャピラリーチューブから製造され、マイクロマニピュレーターやマイクロインジェクションシステムと組み合わせて使用される。その主な機能は、顕微鏡下で選別・固定化された単一の精子を吸引・制御し、安定化された卵子の透明帯および卵膜を貫通させ、精子を卵質内に直接放出することで、細胞質内精子注入を完了させることである。製品設計では、先端形状、内腔形状、テーパープロファイル、屈曲角度、表面仕上げ、および製造の一貫性に重点が置かれており、卵子への機械的損傷を最小限に抑えつつ、信頼性の高い精子操作、制御された卵子穿孔、および正確な細胞質内注入を実現する。ICSI用マイクロピペットは、生殖補助医療におけるマイクロマニピュレーション専用の消耗品であり、注入処置中に卵子を安定化させるために使用されるホールドピペットとは機能的に異なる。 市場の動向 体外受精（IVF）用マイクロマニピュレーションピペット市場は、基本的なガラス製注入ツールから、再現性の向上、卵子への外傷の低減、および胚学者の個別の取り扱い好みに最適化された、高度に標準化されたマイクロツールへと進化している。主要サプライヤーは、単一の汎用仕様ではなく、スパイクの設計、内径、テーパー形状、曲がり角度、および先端から曲がり部までの距離の複数の組み合わせをますます提供するようになっている。流体の制御性を向上させ、注入口径を縮小するために、長い平行壁構造やスリムな設計が開発されている一方、より高い穿刺剛性を求めるユーザーにとっては、剛性の高いショートテーパー設計が依然として重要である。大口径モデルは外科的に採取された精子に対応しており、フラットチップや専用のピエゾ注入ピペットが市場の技術的範囲を拡大している。製造工程の管理もより厳格化されている。CooperSurgical社は自動化生産と反復的な寸法検査を採用している一方、北里（Kitazato）社とASTEC社は個別に検査を行う精密製造を重視しており、ICSION社はカスタマイズされた仕様を提供している。クリーンルームでの製造、個別の滅菌包装、トレーサビリティ、MEAおよびエンドトキシン試験は、二次的な機能ではなく、ますます重要な購入判断基準となりつつある。 タイプ別セグメント スパイク付き スパイクなし 用途別セグメント 不妊治療クリニックおよび体外受精（IVF）センター 病院内生殖医療センター 学術・研究機関の研究所 その他 カテゴリー別セグメント <5.0 μm 5.0–<6.0 μm ≥6.0 μm 部門別セグメント ロング・パラレルウォール ショート・パラレルウォール リジッド・テーパー 企業別 CooperSurgical Nexpring Health Vitrolife Kitazato Sunlight Medical VITROMED ASTEC Labotect Thomas Medical Microtech IVF Synga ARSCI Optimas ICSION Medical Monash Biotech Reproline medical TechBruein SASOmed VitaVitro DEWIN WEGOShingene Medical Lingen Precision Medical Products Diagens Bio Minvitro |
The global Micromanipulation Pipettes for IVF market was valued at US$ 38.72 million in 2025 and is anticipated to reach US$ 55.96 million by 2032, at a CAGR of 5.4% from 2026 to 2032.
Micromanipulation Pipette for IVF is a specialized micromanipulation tool used in assisted reproductive laboratories for intracytoplasmic sperm injection. It is typically manufactured from fine glass capillary tubing with a sharp, beveled or spiked tip and is operated together with a micromanipulator and microinjection system. Its primary function is to aspirate and control a selected and immobilized single sperm under microscopic observation, penetrate the zona pellucida and oolemma of a stabilized oocyte, and release the sperm directly into the ooplasm to complete intracytoplasmic sperm injection. Product design focuses on tip configuration, lumen geometry, taper profile, bending angle, surface finish and manufacturing consistency to provide reliable sperm handling, controlled oocyte penetration and precise cytoplasmic injection while minimizing mechanical damage to the oocyte. ICSI micropipettes are specialized consumables for assisted reproductive micromanipulation and are functionally distinct from holding pipettes, which are used to stabilize the oocyte during the injection procedure.
MARKET TRENDS
The Micromanipulation Pipette for IVF market is evolving from basic glass injection tools toward highly standardized microtools optimized for reproducibility, lower oocyte trauma and embryologist-specific handling preferences. Major suppliers increasingly offer multiple combinations of spike design, lumen diameter, taper geometry, bend angle and tip-to-bend distance rather than a single universal specification. Long parallel-wall and slim designs are being developed to improve fluid control and reduce entry diameter, while rigid short-taper designs remain important for users seeking greater puncture stiffness. Large-bore models address surgically retrieved sperm, and flat-tip or dedicated Piezo injection pipettes are expanding the technical range of the market. Manufacturing is also becoming more controlled: CooperSurgical uses automated production and repeated dimensional inspection, while Kitazato and ASTEC emphasize individually inspected precision manufacturing and ICSION offers customized specifications. Cleanroom manufacture, individual sterile packaging, traceability, MEA and endotoxin testing are increasingly becoming core purchasing considerations rather than secondary features.
Segment by Type
Spiked
Non-Spiked
Segment by Application
Fertility Clinics and IVF Centers
Hospital-Based Reproductive Medicine Centers
Academic and Research Laboratories
Others
Segment by Category
<5.0 μm
5.0–<6.0 μm
≥6.0 μm
Segment by Division
Long Parallel-Wall
Short Parallel-Wall
Rigid-Taper
By Company
CooperSurgical
Nexpring Health
Vitrolife
Kitazato
Sunlight Medical
VITROMED
ASTEC
Labotect
Thomas Medical
Microtech IVF
Synga
ARSCI
Optimas
ICSION Medical
Monash Biotech
Reproline medical
TechBruein
SASOmed
VitaVitro
DEWIN
WEGO Shingene Medical
Lingen Precision Medical Products
Diagens Bio
Minvitro
1 Micromanipulation Pipettes for IVF Market Overview
1.1 Product Definition
1.2 Micromanipulation Pipettes for IVF by Type
1.2.1 Global Micromanipulation Pipettes for IVF Market Value by Type: 2025 vs 2032
1.2.2 Spiked
1.2.3 Non-Spiked
1.3 Micromanipulation Pipettes for IVF by Inner Diameter
1.3.1 Global Micromanipulation Pipettes for IVF Market Value by Inner Diameter: 2025 vs 2032
1.3.2 <5.0 μm
1.3.3 5.0–<6.0 μm
1.3.4 ≥6.0 μm
1.4 Micromanipulation Pipettes for IVF by Taper Design
1.4.1 Global Micromanipulation Pipettes for IVF Market Value by Taper Design: 2025 vs 2032
1.4.2 Long Parallel-Wall
1.4.3 Short Parallel-Wall
1.4.4 Rigid-Taper
1.5 Micromanipulation Pipettes for IVF by Application
1.5.1 Global Micromanipulation Pipettes for IVF Market Value by Application: 2025 vs 2032
1.5.2 Fertility Clinics and IVF Centers
1.5.3 Hospital-Based Reproductive Medicine Centers
1.5.4 Academic and Research Laboratories
1.5.5 Others
1.6 Global Micromanipulation Pipettes for IVF Market Size Estimates and Forecasts
1.6.1 Global Micromanipulation Pipettes for IVF Revenue 2021–2032
1.6.2 Global Micromanipulation Pipettes for IVF Sales 2021–2032
1.6.3 Global Micromanipulation Pipettes for IVF Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Micromanipulation Pipettes for IVF Market Competition by Manufacturers
2.1 Global Micromanipulation Pipettes for IVF Sales Market Share by Manufacturers (2021–2026)
2.2 Global Micromanipulation Pipettes for IVF Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Micromanipulation Pipettes for IVF Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Micromanipulation Pipettes for IVF, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Micromanipulation Pipettes for IVF, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Micromanipulation Pipettes for IVF, Product Types and Applications
2.7 Global Key Manufacturers of Micromanipulation Pipettes for IVF, Date of Entry into the Industry
2.8 Global Micromanipulation Pipettes for IVF Market Competitive Situation and Trends
2.8.1 Global Micromanipulation Pipettes for IVF Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Micromanipulation Pipettes for IVF Players Market Share by Revenue
2.8.3 Global Micromanipulation Pipettes for IVF Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Micromanipulation Pipettes for IVF Market Scenario by Region
3.1 Global Micromanipulation Pipettes for IVF Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Micromanipulation Pipettes for IVF Sales by Region: 2021–2032
3.2.1 Global Micromanipulation Pipettes for IVF Sales by Region: 2021–2026
3.2.2 Global Micromanipulation Pipettes for IVF Sales by Region: 2027–2032
3.3 Global Micromanipulation Pipettes for IVF Revenue by Region: 2021–2032
3.3.1 Global Micromanipulation Pipettes for IVF Revenue by Region: 2021–2026
3.3.2 Global Micromanipulation Pipettes for IVF Revenue by Region: 2027–2032
3.4 North America Micromanipulation Pipettes for IVF Market Facts & Figures by Country
3.4.1 North America Micromanipulation Pipettes for IVF Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Micromanipulation Pipettes for IVF Sales by Country (2021–2032)
3.4.3 North America Micromanipulation Pipettes for IVF Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Micromanipulation Pipettes for IVF Market Facts & Figures by Country
3.5.1 Europe Micromanipulation Pipettes for IVF Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Micromanipulation Pipettes for IVF Sales by Country (2021–2032)
3.5.3 Europe Micromanipulation Pipettes for IVF Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Micromanipulation Pipettes for IVF Market Facts & Figures by Region
3.6.1 Asia Pacific Micromanipulation Pipettes for IVF Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Micromanipulation Pipettes for IVF Sales by Region (2021–2032)
3.6.3 Asia Pacific Micromanipulation Pipettes for IVF Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Micromanipulation Pipettes for IVF Market Facts & Figures by Country
3.7.1 Latin America Micromanipulation Pipettes for IVF Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Micromanipulation Pipettes for IVF Sales by Country (2021–2032)
3.7.3 Latin America Micromanipulation Pipettes for IVF Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Micromanipulation Pipettes for IVF Market Facts & Figures by Country
3.8.1 Middle East and Africa Micromanipulation Pipettes for IVF Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Micromanipulation Pipettes for IVF Sales by Country (2021–2032)
3.8.3 Middle East and Africa Micromanipulation Pipettes for IVF Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Micromanipulation Pipettes for IVF Sales by Type (2021–2032)
4.1.1 Global Micromanipulation Pipettes for IVF Sales by Type (2021–2026)
4.1.2 Global Micromanipulation Pipettes for IVF Sales by Type (2027–2032)
4.1.3 Global Micromanipulation Pipettes for IVF Sales Market Share by Type (2021–2032)
4.2 Global Micromanipulation Pipettes for IVF Revenue by Type (2021–2032)
4.2.1 Global Micromanipulation Pipettes for IVF Revenue by Type (2021–2026)
4.2.2 Global Micromanipulation Pipettes for IVF Revenue by Type (2027–2032)
4.2.3 Global Micromanipulation Pipettes for IVF Revenue Market Share by Type (2021–2032)
4.3 Global Micromanipulation Pipettes for IVF Price by Type (2021–2032)
5 Segment by Application
5.1 Global Micromanipulation Pipettes for IVF Sales by Application (2021–2032)
5.1.1 Global Micromanipulation Pipettes for IVF Sales by Application (2021–2026)
5.1.2 Global Micromanipulation Pipettes for IVF Sales by Application (2027–2032)
5.1.3 Global Micromanipulation Pipettes for IVF Sales Market Share by Application (2021–2032)
5.2 Global Micromanipulation Pipettes for IVF Revenue by Application (2021–2032)
5.2.1 Global Micromanipulation Pipettes for IVF Revenue by Application (2021–2026)
5.2.2 Global Micromanipulation Pipettes for IVF Revenue by Application (2027–2032)
5.2.3 Global Micromanipulation Pipettes for IVF Revenue Market Share by Application (2021–2032)
5.3 Global Micromanipulation Pipettes for IVF Price by Application (2021–2032)
6 Key Companies Profiled
6.1 CooperSurgical
6.1.1 CooperSurgical Company Information
6.1.2 CooperSurgical Description and Business Overview
6.1.3 CooperSurgical Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 CooperSurgical Micromanipulation Pipettes for IVF Product Portfolio
6.1.5 CooperSurgical Recent Developments/Updates
6.2 Nexpring Health
6.2.1 Nexpring Health Company Information
6.2.2 Nexpring Health Description and Business Overview
6.2.3 Nexpring Health Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Nexpring Health Micromanipulation Pipettes for IVF Product Portfolio
6.2.5 Nexpring Health Recent Developments/Updates
6.3 Vitrolife
6.3.1 Vitrolife Company Information
6.3.2 Vitrolife Description and Business Overview
6.3.3 Vitrolife Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Vitrolife Micromanipulation Pipettes for IVF Product Portfolio
6.3.5 Vitrolife Recent Developments/Updates
6.4 Kitazato
6.4.1 Kitazato Company Information
6.4.2 Kitazato Description and Business Overview
6.4.3 Kitazato Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Kitazato Micromanipulation Pipettes for IVF Product Portfolio
6.4.5 Kitazato Recent Developments/Updates
6.5 Sunlight Medical
6.5.1 Sunlight Medical Company Information
6.5.2 Sunlight Medical Description and Business Overview
6.5.3 Sunlight Medical Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Sunlight Medical Micromanipulation Pipettes for IVF Product Portfolio
6.5.5 Sunlight Medical Recent Developments/Updates
6.6 VITROMED
6.6.1 VITROMED Company Information
6.6.2 VITROMED Description and Business Overview
6.6.3 VITROMED Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 VITROMED Micromanipulation Pipettes for IVF Product Portfolio
6.6.5 VITROMED Recent Developments/Updates
6.7 ASTEC
6.7.1 ASTEC Company Information
6.7.2 ASTEC Description and Business Overview
6.7.3 ASTEC Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 ASTEC Micromanipulation Pipettes for IVF Product Portfolio
6.7.5 ASTEC Recent Developments/Updates
6.8 Labotect
6.8.1 Labotect Company Information
6.8.2 Labotect Description and Business Overview
6.8.3 Labotect Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Labotect Micromanipulation Pipettes for IVF Product Portfolio
6.8.5 Labotect Recent Developments/Updates
6.9 Thomas Medical
6.9.1 Thomas Medical Company Information
6.9.2 Thomas Medical Description and Business Overview
6.9.3 Thomas Medical Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Thomas Medical Micromanipulation Pipettes for IVF Product Portfolio
6.9.5 Thomas Medical Recent Developments/Updates
6.10 Microtech IVF
6.10.1 Microtech IVF Company Information
6.10.2 Microtech IVF Description and Business Overview
6.10.3 Microtech IVF Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Microtech IVF Micromanipulation Pipettes for IVF Product Portfolio
6.10.5 Microtech IVF Recent Developments/Updates
6.11 Synga
6.11.1 Synga Company Information
6.11.2 Synga Description and Business Overview
6.11.3 Synga Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Synga Micromanipulation Pipettes for IVF Product Portfolio
6.11.5 Synga Recent Developments/Updates
6.12 ARSCI
6.12.1 ARSCI Company Information
6.12.2 ARSCI Description and Business Overview
6.12.3 ARSCI Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 ARSCI Micromanipulation Pipettes for IVF Product Portfolio
6.12.5 ARSCI Recent Developments/Updates
6.13 Optimas
6.13.1 Optimas Company Information
6.13.2 Optimas Description and Business Overview
6.13.3 Optimas Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Optimas Micromanipulation Pipettes for IVF Product Portfolio
6.13.5 Optimas Recent Developments/Updates
6.14 ICSION Medical
6.14.1 ICSION Medical Company Information
6.14.2 ICSION Medical Description and Business Overview
6.14.3 ICSION Medical Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 ICSION Medical Micromanipulation Pipettes for IVF Product Portfolio
6.14.5 ICSION Medical Recent Developments/Updates
6.15 Monash Biotech
6.15.1 Monash Biotech Company Information
6.15.2 Monash Biotech Description and Business Overview
6.15.3 Monash Biotech Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Monash Biotech Micromanipulation Pipettes for IVF Product Portfolio
6.15.5 Monash Biotech Recent Developments/Updates
6.16 Reproline medical
6.16.1 Reproline medical Company Information
6.16.2 Reproline medical Description and Business Overview
6.16.3 Reproline medical Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Reproline medical Micromanipulation Pipettes for IVF Product Portfolio
6.16.5 Reproline medical Recent Developments/Updates
6.17 TechBruein
6.17.1 TechBruein Company Information
6.17.2 TechBruein Description and Business Overview
6.17.3 TechBruein Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 TechBruein Micromanipulation Pipettes for IVF Product Portfolio
6.17.5 TechBruein Recent Developments/Updates
6.18 SASOmed
6.18.1 SASOmed Company Information
6.18.2 SASOmed Description and Business Overview
6.18.3 SASOmed Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 SASOmed Micromanipulation Pipettes for IVF Product Portfolio
6.18.5 SASOmed Recent Developments/Updates
6.19 VitaVitro
6.19.1 VitaVitro Company Information
6.19.2 VitaVitro Description and Business Overview
6.19.3 VitaVitro Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 VitaVitro Micromanipulation Pipettes for IVF Product Portfolio
6.19.5 VitaVitro Recent Developments/Updates
6.20 DEWIN
6.20.1 DEWIN Company Information
6.20.2 DEWIN Description and Business Overview
6.20.3 DEWIN Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 DEWIN Micromanipulation Pipettes for IVF Product Portfolio
6.20.5 DEWIN Recent Developments/Updates
6.21 WEGO Shingene Medical
6.21.1 WEGO Shingene Medical Company Information
6.21.2 WEGO Shingene Medical Description and Business Overview
6.21.3 WEGO Shingene Medical Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 WEGO Shingene Medical Micromanipulation Pipettes for IVF Product Portfolio
6.21.5 WEGO Shingene Medical Recent Developments/Updates
6.22 Lingen Precision Medical Products
6.22.1 Lingen Precision Medical Products Company Information
6.22.2 Lingen Precision Medical Products Description and Business Overview
6.22.3 Lingen Precision Medical Products Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 Lingen Precision Medical Products Micromanipulation Pipettes for IVF Product Portfolio
6.22.5 Lingen Precision Medical Products Recent Developments/Updates
6.23 Diagens Bio
6.23.1 Diagens Bio Company Information
6.23.2 Diagens Bio Description and Business Overview
6.23.3 Diagens Bio Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.23.4 Diagens Bio Micromanipulation Pipettes for IVF Product Portfolio
6.23.5 Diagens Bio Recent Developments/Updates
6.24 Minvitro
6.24.1 Minvitro Company Information
6.24.2 Minvitro Description and Business Overview
6.24.3 Minvitro Micromanipulation Pipettes for IVF Sales, Revenue, and Gross Margin (2021–2026)
6.24.4 Minvitro Micromanipulation Pipettes for IVF Product Portfolio
6.24.5 Minvitro Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Micromanipulation Pipettes for IVF Industry Chain Analysis
7.2 Micromanipulation Pipettes for IVF Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Micromanipulation Pipettes for IVF Production Mode & Process Analysis
7.4 Micromanipulation Pipettes for IVF Sales and Marketing
7.4.1 Micromanipulation Pipettes for IVF Sales Channels
7.4.2 Micromanipulation Pipettes for IVF Distributors
7.5 Micromanipulation Pipettes for IVF Customer Analysis
8 Micromanipulation Pipettes for IVF Market Dynamics
8.1 Micromanipulation Pipettes for IVF Industry Trends
8.2 Micromanipulation Pipettes for IVF Market Drivers
8.3 Micromanipulation Pipettes for IVF Market Challenges
8.4 Micromanipulation Pipettes for IVF Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
冷媒の世界市場2025-2033 The global refrigerant market size reached USD 21.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 40.7 Billion by 2033, exhibiting a growth rate (CAGR) of 8.06% during 2025-2033. The increasing need for cooling solutions due to global climate changes, continual advanc…- ペットフードの日本市場（2026年～2034年） The Japan pet food market size was valued at USD 6.4 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 9.7 Billion by 2034, exhibiting a CAGR of 4.40% from 2026-2034. Rising pet ownership and increasing focus on pet health, demand for premium, functional, and sustainabl…
- 建設機械の日本市場（2026年～2034年） Japan construction equipment market size reached USD 13.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 22.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.20% during 2026-2034. The increasing investment in infrastructure projects, such as roads, bridges, airpo…
- 建設機械レンタルの日本市場（2026年～2034年） Japan construction equipment rental market size reached USD 12.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 20.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.78% during 2026-2034. The inflating popularity of rental and leasing services and the growing adva…
- マッサージチェアの日本市場（2026年～2034年） The Japan massage chair market size reached USD 241.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 372.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.93% during 2026-2034. The market is driven by an aging population seeking pain relief, rising health awarene…